Table 2.
Current and past clinical trials for MCC-related therapy
| Drug | Mechanism of action | Phase | Indentifier |
|---|---|---|---|
| MK2206 | Akt inhibitor | Phase2 | NCT01802320 |
| Alisertib | Aurora A kinase inhibitor | Phase1 | NCT01923337 |
| Oxaliplatin | DNA synthesis inhibitor | Phase1 Phase2 Phase3 |
NCT00005036 NCT00060411 NCT00217737 NCT01643499 NCT01652196 |
| 6,8-Bis(benzylthio)octanoic acid | E1α PDH modulator | Phase1 | NCT02232152 |
| Cetuximab | EGFR inhibitor | Early phase1 Phase1 Phase2 |
NCT00100841 NCT00835679 NCT01198535 |
| Dasatinib | EGFR inhibitor | Early phase1 | NCT00835679 |
| Erlotinib | EGFR inhibitor | Phase1 | NCT00060411 |
| Gefitinib | EGFR inhibitor | Phase2 | NCT00052585 |
| Panitumumab | EGFR inhibitor | Phase2 | NCT01285102 |
| Gamma-seretase inhibitor RO4929097 | Gamma-seretase inhibitor | Phase1 | NCT01198535 |
| Recombinant inferferon gamma | Macrophage activation factor | Phase1 Phase2 |
NCT00002796 |
| Fluorouracil | Thymidylate synthase blocking | Phase1 Phase2 Phase3 |
NCT00002796 NCT00005036 NCT00052585 NCT00060411 NCT00217737 NCT01285102 NCT01643499 NCT01652196 NCT02232152 NCT02235324 |
| Irinotecan | Topoisomerase inhibitor | Phase1 Phase2 Phase3 |
NCT00005036 NCT00052585 NCT01285102 NCT01643499 NCT01923337 NCT04088786 |
| Aflibercept | VEGF inhibitor | Phase2 |
NCT01652196 NCT02235324 |
| Bevacizumab | VEGF inhibitor | Phase1 Phase2 Phase3 |
NCT00060411 NCT00100841 NCT00217737 |